[go: up one dir, main page]

MX2015011898A - Compuestos de pirazolo y usos de los mismos. - Google Patents

Compuestos de pirazolo y usos de los mismos.

Info

Publication number
MX2015011898A
MX2015011898A MX2015011898A MX2015011898A MX2015011898A MX 2015011898 A MX2015011898 A MX 2015011898A MX 2015011898 A MX2015011898 A MX 2015011898A MX 2015011898 A MX2015011898 A MX 2015011898A MX 2015011898 A MX2015011898 A MX 2015011898A
Authority
MX
Mexico
Prior art keywords
compounds
pyrazolo compounds
pyrazolo
present
demethylses
Prior art date
Application number
MX2015011898A
Other languages
English (en)
Inventor
Sharada Labadie
Liangjun
Birong Zhang
Brian K Albrecht
Steven F Bellon
Victor S Gehling
Jean-Christophe Harmange
Peter DRAGOVICH
Dan Ortwine
Kwong Wah Lai
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2015011898A publication Critical patent/MX2015011898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se proporcionan compuestos útiles como inhibidores de una o más demetilasas de histona, tales como KDM5. La invención igualmente proporciona composiciones farmacéuticamente aceptables que comprenden los compuestos de la presente invención y los métodos para usar la presente composición en el tratamiento de diversos trastornos.
MX2015011898A 2013-03-13 2014-03-13 Compuestos de pirazolo y usos de los mismos. MX2015011898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778759P 2013-03-13 2013-03-13
PCT/CN2014/000262 WO2014139326A1 (en) 2013-03-13 2014-03-13 Pyrazolo compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2015011898A true MX2015011898A (es) 2016-05-05

Family

ID=51529954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011898A MX2015011898A (es) 2013-03-13 2014-03-13 Compuestos de pirazolo y usos de los mismos.

Country Status (10)

Country Link
US (2) US20140275092A1 (es)
EP (1) EP2970307B1 (es)
JP (2) JP6660182B2 (es)
KR (1) KR20150130491A (es)
CN (1) CN105980386B (es)
BR (1) BR112015022545A2 (es)
CA (1) CA2904760A1 (es)
MX (1) MX2015011898A (es)
RU (1) RU2015143517A (es)
WO (1) WO2014139326A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011898A (es) * 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
EP3004396B1 (en) * 2013-06-06 2019-10-16 The General Hospital Corporation Compositions for the treatment of cancer
CA2922925A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
JP6783230B2 (ja) * 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
AU2015340215B2 (en) 2014-10-29 2018-11-15 Dong-A St Co., Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)
BR112018003588A2 (pt) 2015-08-26 2018-09-25 Blueprint Medicines Corp compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
SG11201803920TA (en) 2015-11-19 2018-06-28 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AU2017271990B2 (en) 2016-05-27 2019-12-19 Gilead Sciences, Inc. Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
PT3507276T (pt) 2016-09-02 2022-01-11 Gilead Sciences Inc Compostos moduladores do recetor de tipo toll
EP3525786A4 (en) * 2016-10-12 2020-03-18 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
CN106883235B (zh) * 2016-12-29 2019-04-30 天津国际生物医药联合研究院 恶二唑类化合物的制备和应用
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
US11124795B2 (en) 2017-02-28 2021-09-21 University Of Massachusetts Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
IL270154B (en) 2017-04-27 2022-07-01 Takeda Pharmaceuticals Co Heterocyclic compound
CA3075751A1 (en) 2017-09-15 2019-03-21 Aduro Biotech, Inc. Pyrazolopyrimidinone compounds and uses thereof
CN111433210A (zh) * 2017-12-20 2020-07-17 诺华股份有限公司 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CU20200084A7 (es) 2018-05-17 2021-06-08 Bayer Ag Derivados sustituidos de la carboxamida dihidropirazolo pirazina
IL279829B2 (en) * 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as A2A/A2B inhibitors
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020218470A1 (ja) * 2019-04-26 2020-10-29 国立大学法人大阪大学 エピジェネティックスを標的とした新規医薬
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US20220289751A1 (en) * 2019-07-17 2022-09-15 Ono Pharmaceutical Co., Ltd. Compound having kdm5 inhibitory activity and pharmaceutical use thereof
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CA3149557A1 (en) 2019-09-30 2021-04-08 Scott J. Balsitis Hbv vaccines and methods treating hbv
MX2022006281A (es) 2019-11-25 2022-06-08 Amgen Inc Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
ES3054072T3 (en) 2020-08-07 2026-01-29 Gilead Sciences Inc Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN113501828B (zh) * 2021-07-07 2023-02-21 上海毕得医药科技股份有限公司 2，8-二氧杂螺[4.5]癸烷-1-酮及其制备方法和应用
IL316462A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2024307018A1 (en) * 2023-06-28 2025-11-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Aromatic nitrogen-containing compounds, preparation methods and medicinal uses thereof
JP7734361B2 (ja) * 2023-09-05 2025-09-05 セレイドセラピューティクス株式会社 化合物又はその塩及びその製造方法、化合物又はその塩を含む医薬品組成物及びその製造方法
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
WO1979000733A1 (en) 1978-03-10 1979-10-04 Ici Ltd Heterocyclic compounds
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE3722072A1 (de) 1987-07-01 1989-01-12 Schering Ag 6,7-dihydro-pyrazolo(1,5-a)(1,3,5) triazin-2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und pflanzenwuchsregulierender wirkung
US4950585A (en) 1987-08-18 1990-08-21 Konica Corporation Coupler for photographic use
CA1330079C (en) * 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
JP3295149B2 (ja) * 1991-12-26 2002-06-24 ポーラ化成工業株式会社 ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP0976754B1 (en) 1997-02-14 2004-07-14 Pola Chemical Industries, Inc. Remedies/preventives for respiratory diseases
IN188411B (es) 1997-03-27 2002-09-21 Yuhan Corp
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
HUP0004286A3 (en) 1997-11-06 2002-01-28 American Cyanamid Co Madison Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
JPH11184043A (ja) 1997-12-17 1999-07-09 Konica Corp ハロゲン化銀カラー写真感光材料及びカラープルーフの作製方法
JP3687900B2 (ja) 1998-11-19 2005-08-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド
JP2000153671A (ja) 1998-11-20 2000-06-06 Fuji Photo Film Co Ltd 感熱記録材料
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP2002326462A (ja) 2001-04-27 2002-11-12 Fuji Photo Film Co Ltd 感熱記録材料
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
NZ538223A (en) 2002-08-26 2008-03-28 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
KR20050057072A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
JP4700344B2 (ja) * 2002-09-04 2011-06-15 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
CA2497544C (en) 2002-09-04 2010-11-02 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
CN1310918C (zh) * 2002-09-04 2007-04-18 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶
CN1829717A (zh) * 2003-06-03 2006-09-06 巴斯福股份公司 取代的吡唑并嘧啶、其生产方法及其在防治有害真菌中的用途以及包含所述化合物的试剂
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
DE10357569A1 (de) * 2003-12-10 2005-07-07 Bayer Cropscience Ag Pyrazolopyrimidine
US7642361B2 (en) 2004-01-09 2010-01-05 Eli Lilly And Company Thiophene and furan compounds
WO2005103052A1 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
JP2006045156A (ja) 2004-08-06 2006-02-16 Sumitomo Pharmaceut Co Ltd 縮合ピラゾール誘導体
ES2327145T3 (es) 2004-12-21 2009-10-26 Schering Corporation Anatagonistas del receptor de adenosina a2a de pirazolo(1,5-a)pirimidina sustituidos.
AU2006247695B2 (en) 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
EP2005190B2 (en) 2006-03-14 2013-11-27 Københavns Universitet Inhibition of gasc1
EP2094697A1 (en) * 2006-11-23 2009-09-02 Novartis AG 5-sulfanylmethyl-pyrazolo [1,5-a]pyrimidin-7-ol derivatives as cxcr2 antagonists
ZA200904321B (en) * 2006-12-22 2010-08-25 Avexa Ltd Bicyclic pyrimidinones and uses thereof
EP1950286B1 (en) 2007-01-26 2015-08-12 Universitätsklinikum Freiburg Tri-demethylation-capable protein complex, method of its preparation and its use
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011135491A1 (en) * 2010-04-26 2011-11-03 Basf Se Herbicidal azolopyrimidines
BR112013008695A2 (pt) * 2010-09-27 2016-06-21 Proximagen Ltd compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2
US10953012B2 (en) * 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
CN102241678B (zh) * 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
RU2014146778A (ru) * 2012-05-23 2016-07-10 Савира Фармасьютикалз Гмбх Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания
BR112014029016A8 (pt) 2012-05-23 2018-01-09 European Molecular Biology Laboratory derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
GB2505869A (en) 2012-07-12 2014-03-19 Imi Cornelius Uk Ltd A beverage cooler comprising an ice bank which has a selectable size
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP2934145B1 (en) 2012-12-19 2017-11-15 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2014119752A1 (ja) 2013-01-31 2014-08-07 三井化学アグロ株式会社 縮合環ピリミジン化合物及びそれを含む有害生物防除剤
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
CA2922925A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds

Also Published As

Publication number Publication date
HK1226056A1 (zh) 2017-09-22
JP7014765B2 (ja) 2022-02-01
EP2970307B1 (en) 2020-03-11
BR112015022545A2 (pt) 2017-07-18
JP6660182B2 (ja) 2020-03-11
JP2016510773A (ja) 2016-04-11
US20160060267A1 (en) 2016-03-03
US10035801B2 (en) 2018-07-31
EP2970307A1 (en) 2016-01-20
RU2015143517A (ru) 2017-04-19
CN105980386B (zh) 2021-08-13
EP2970307A4 (en) 2016-10-05
JP2020037590A (ja) 2020-03-12
CN105980386A (zh) 2016-09-28
US20140275092A1 (en) 2014-09-18
RU2015143517A3 (es) 2018-03-30
KR20150130491A (ko) 2015-11-23
WO2014139326A1 (en) 2014-09-18
CA2904760A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
IN2014DN10386A (es)
NZ700928A (en) Dna-pk inhibitors
MY189912A (en) Substituted xanthines and methods of use thereof
HK1216175A1 (zh) 治療性化合物和組合物
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
PH12014501991B1 (en) Phenicol antibacterials
CL2015002897A1 (es) Inhibidores de bace1
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.